Takeda Pharmaceutical Li... (TAK)
NYSE: TAK
· Real-Time Price · USD
13.79
0.07 (0.51%)
At close: Oct 14, 2025, 10:32 AM
0.51% (1D)
| Bid | 13.77 |
| Market Cap | 43.54B |
| Revenue (ttm) | 4,480.2B |
| Net Income (ttm) | 136.88B |
| EPS (ttm) | 0.28 |
| PE Ratio (ttm) | 49.23 |
| Forward PE | 0.17 |
| Analyst | n/a |
| Dividends | $0.92 |
| Ask | 13.79 |
| Volume | 979,645 |
| Avg. Volume (20D) | 3,729,318 |
| Open | 13.86 |
| Previous Close | 13.72 |
| Day's Range | 13.76 - 13.86 |
| 52-Week Range | 12.80 - 15.69 |
| Beta | 0.26 |
| Ex-Dividend Date | Sep 30, 2025 |
Takeda Pharmaceutical Limited is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
-5.25%
Takeda Pharmaceutical shares are trading lower fol...
Unlock content with
Pro Subscription
7 months ago
+2.98%
Takeda Pharmaceutical shares are trading higher after the company announced topline results from phase 3 verify study of rusfertide in patients with polycythemia vera.
2 weeks ago · seekingalpha.com
Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion AnnuallyTakeda (TAK) offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. TAK's pipeline includes first-in-class and best-in-class candidates, but ...
1 month ago · businesswire.com
Takeda Appoints Rhonda Pacheco President of the U.S. Business UnitCAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, eff...
